NASDAQ:TOI Oncology Institute (TOI) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free TOI Stock Alerts $1.58 -0.26 (-14.13%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.52▼$1.7850-Day Range$1.36▼$2.1752-Week Range$0.33▼$2.66Volume289,467 shsAverage Volume135,816 shsMarket Capitalization$116.53 millionP/E RatioN/ADividend YieldN/APrice Target$2.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Oncology Institute alerts: Email Address Oncology Institute MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside42.4% Upside$2.25 Price TargetShort InterestHealthy0.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.22Based on 10 Articles This WeekInsider TradingSelling Shares$137,838 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.51) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.68 out of 5 starsMedical Sector482nd out of 938 stocksMedical Care Facilities Industry1st out of 1 stocks 3.5 Analyst's Opinion Consensus RatingOncology Institute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.25, Oncology Institute has a forecasted upside of 42.4% from its current price of $1.58.Amount of Analyst CoverageOncology Institute has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.76% of the float of Oncology Institute has been sold short.Short Interest Ratio / Days to CoverOncology Institute has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncology Institute has recently increased by 3.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOncology Institute does not currently pay a dividend.Dividend GrowthOncology Institute does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TOI. Previous Next 2.1 News and Social Media Coverage News SentimentOncology Institute has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Oncology Institute this week, compared to 3 articles on an average week.Search Interest10 people have searched for TOI on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows3 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncology Institute insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,838.00 in company stock.Percentage Held by Insiders13.10% of the stock of Oncology Institute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.86% of the stock of Oncology Institute is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Oncology Institute are expected to grow in the coming year, from ($0.51) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncology Institute is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncology Institute is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncology Institute has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Oncology Institute Stock (NASDAQ:TOI)The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.Read More TOI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TOI Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comQ4 2023 Oncology Institute Inc Earnings CallMarch 27, 2024 | benzinga.comRecap: Oncology Institute Q4 EarningsMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 27, 2024 | finance.yahoo.comThe Oncology Institute Inc (TOI) Reports Mixed Q4 and Full Year 2023 ResultsMarch 27, 2024 | globenewswire.comThe Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024March 24, 2024 | msn.comFree HPV vaccine given to 135 survivors of sexual abuseMarch 24, 2024 | msn.comPhiladelphia College of Osteopathic Medicine and The Wistar Institute Launch Joint Cancer Biology Ph.D. ProgramMarch 23, 2024 | msn.comDoctors say diagnosis of Princess Catherine’s cancer is a familiar scenarioMarch 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 21, 2024 | msn.comPCOM and The Wistar Institute are launching a cancer biology graduate programMarch 20, 2024 | markets.businessinsider.comPCOM, The Wistar Institute Announce Cancer Biology Graduate ProgramMarch 20, 2024 | americanbankingnews.comOncology Institute (TOI) Scheduled to Post Quarterly Earnings on WednesdayMarch 19, 2024 | msn.comPGIMER honoured at 5th Entrepreneur and Achiever Award 2024March 19, 2024 | msn.comNew imaging technology for diagnosing and treating bowel cancer patientsMarch 15, 2024 | msn.comFake cancer drugs racket: Delhi Police arrest IIT grad | All about the case & probe so farMarch 14, 2024 | globenewswire.comMaxHealth & The Oncology Institute Expand Value-Based Care PartnershipMarch 11, 2024 | msn.com5 Rules for Setting up Home Office as per VastuMarch 10, 2024 | msn.comWhat’s driving cancer rate in Malwa, the cotton belt of the country?March 8, 2024 | msn.comMiraculous recovery: Man stuns doctors as world-first treatment ‘eradicates cancer’March 7, 2024 | msn.comNeoadjuvant Chemo Adds Significant Treatment Benefit in Penile CancerMarch 7, 2024 | msn.comExclusive: 'Radiation therapy is curative in many cancers and has seen significant advancement'March 6, 2024 | globenewswire.comThe Oncology Institute Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Conference CallMarch 4, 2024 | msn.comISRO chief S Somanath diagnosed with cancer on Aditya-L1 launch day: All about the diseaseMarch 3, 2024 | msn.comJefferies cautious on Value Based Care providers; favors ASTH, PRVA, TOIFebruary 28, 2024 | msn.comTata Institute claims successful cancer treatment with just Rs 100 tabletFebruary 27, 2024 | globenewswire.comThe Oncology Institute to Participate at Upcoming Investor ConferencesFebruary 25, 2024 | msn.comAI-based app for cancer care clicks with patientsSee More Headlines Receive TOI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Care Facilities Sub-IndustryN/A Current SymbolNASDAQ:TOI CUSIPN/A CIK1799191 Webtheoncologyinstitute.com Phone562-735-3226FaxN/AEmployees750Year FoundedN/APrice Target and Rating Average Stock Price Target$2.25 High Stock Price Target$2.50 Low Stock Price Target$2.00 Potential Upside/Downside+42.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$150,000.00 Net Margins-23.82% Pretax Margin-24.34% Return on Equity-61.02% Return on Assets-24.43% Debt Debt-to-Equity Ratio1.19 Current Ratio4.71 Quick Ratio4.34 Sales & Book Value Annual Sales$252.48 million Price / Sales0.46 Cash Flow$0.02 per share Price / Cash Flow104.58 Book Value$1.68 per share Price / Book0.94Miscellaneous Outstanding Shares73,750,000Free Float64,088,000Market Cap$116.53 million OptionableNot Optionable Beta0.71 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Richard Alan Barasch (Age 70)Executive Chairman of the Board Mr. Mihir Arunkumar Shah CPA (Age 46)Chief Financial Officer & Principal Accounting Officer Comp: $393.65kMs. Hilda Agajanian M.B.A.Founder & Chief Growth OfficerDr. Richy Agajanian M.D.Founder & Chief Clinical OfficerMr. Rakesh Singh M.B.A.Director of TechnologyMr. Mark Hueppelsheuser Esq.General CounselMr. Khurrum Shah J.D.M.B.A., Senior Vice President of ComplianceMs. Julie KorinkeDirector of Marketing & CommunicationsMs. Laura SzitarChief People OfficerDr. Yale D. Podnos F.A.C.S. (Age 52)M.D., M.P.H., Chief Medical Officer & President of Practice Comp: $345.02kMore ExecutivesKey CompetitorsSHL TelemedicineNASDAQ:SHLTPono Capital TwoNASDAQ:PTWOLifeMDNASDAQ:LFMDETAO InternationalNASDAQ:ETAOCardiol TherapeuticsNASDAQ:CRDLView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 19,359 shares on 3/11/2024Ownership: 2.410%Vanguard Group Inc.Bought 19,359 shares on 2/15/2024Ownership: 2.410%Citadel Advisors LLCBought 101,123 shares on 2/15/2024Ownership: 0.195%Prelude Capital Management LLCSold 30,240 shares on 2/15/2024Ownership: 0.027%Balyasny Asset Management L.P.Bought 815,458 shares on 2/14/2024Ownership: 1.699%View All Insider TransactionsView All Institutional Transactions TOI Stock Analysis - Frequently Asked Questions Should I buy or sell Oncology Institute stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncology Institute in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TOI shares. View TOI analyst ratings or view top-rated stocks. What is Oncology Institute's stock price target for 2024? 1 analysts have issued 1 year target prices for Oncology Institute's stock. Their TOI share price targets range from $2.00 to $2.50. On average, they anticipate the company's stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 42.4% from the stock's current price. View analysts price targets for TOI or view top-rated stocks among Wall Street analysts. How have TOI shares performed in 2024? Oncology Institute's stock was trading at $2.04 at the start of the year. Since then, TOI shares have decreased by 22.5% and is now trading at $1.58. View the best growth stocks for 2024 here. When is Oncology Institute's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TOI earnings forecast. What guidance has Oncology Institute issued on next quarter's earnings? Oncology Institute updated its FY 2024 earnings guidance on Wednesday, March, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400.0 million-$415.0 million, compared to the consensus revenue estimate of $378.8 million. Who are Oncology Institute's major shareholders? Oncology Institute's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Josh Arnold Investment Consultant LLC (2.52%), Vanguard Group Inc. (2.41%), Vanguard Group Inc. (2.41%), Balyasny Asset Management L.P. (1.70%), Kent Lake Capital LLC (1.47%) and Cincinnati Insurance Co. (0.95%). Insiders that own company stock include Brad Hively, Havencrest Healthcare Partners, Matthew P Miller, Mohit Kaushal, Richard A Barasch and Richy Agajanian. View institutional ownership trends. How do I buy shares of Oncology Institute? Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TOI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Oncology Institute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.